Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2012 / Article

Research Article | Open Access

Volume 2012 |Article ID 636848 | https://doi.org/10.1155/2012/636848

Wei-Hsin Chen, Jason T. C. Tzen, Ching Liang Hsieh, Yung Hsiang Chen, Tzu-Jou Lin, Shih-Yin Chen, Yi-Wen Lin, "Attenuation of TRPV1 and TRPV4 Expression and Function in Mouse Inflammatory Pain Models Using Electroacupuncture", Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 636848, 12 pages, 2012. https://doi.org/10.1155/2012/636848

Attenuation of TRPV1 and TRPV4 Expression and Function in Mouse Inflammatory Pain Models Using Electroacupuncture

Academic Editor: Shao Li
Received27 Aug 2012
Revised15 Oct 2012
Accepted18 Oct 2012
Published13 Nov 2012


Although pain is a major human affliction, our understanding of pain mechanisms is limited. TRPV1 (transient receptor potential vanilloid subtype 1) and TRPV4 are two crucial receptors involved in inflammatory pain, but their roles in EA- (electroacupuncture-) mediated analgesia are unknown. We injected mice with carrageenan (carra) or a complete Freund’s adjuvant (CFA) to model inflammatory pain and investigated the analgesic effect of EA using animal behavior tests, immunostaining, Western blotting, and a whole-cell recording technique. The inflammatory pain model mice developed both mechanical and thermal hyperalgesia. Notably, EA at the ST36 acupoint reversed these phenomena, indicating its curative effect in inflammatory pain. The protein levels of TRPV1 and TRPV4 in DRG (dorsal root ganglion) neurons were both increased at day 4 after the initiation of inflammatory pain and were attenuated by EA, as demonstrated by immunostaining and Western blot analysis. We verified DRG electrophysiological properties to confirm that EA ameliorated peripheral nerve hyperexcitation. Our results indicated that the AP (action potential) threshold, rise time, and fall time, and the percentage and amplitude of TRPV1 and TRPV4 were altered by EA, indicating that EA has an antinociceptive role in inflammatory pain. Our results demonstrate a novel role for EA in regulating TRPV1 and TRPV4 protein expression and nerve excitation in mouse inflammatory pain models.

1. Introduction

Pain, which affects more than 20% of the population worldwide, is a complicated therapeutic challenge with mechanisms that are not fully understood. Pain can be evoked by tissue damage, noxious environmental stimuli, hypoxia, acidosis, and inflammation [1, 2]. Tissue damage causes the injured regions to release inflammatory mediators such as bradykinin, prostaglandins, protons, and neurotransmitters, which activate nerve terminals to pain signal transduction [3].

The TRPV (transient receptor potential vanilloid) family is highly associated with nervous system functions such as pain, memory, and mechanical sensations [4]. The TRPV family includes six subtypes—TRPV1, TRPV2, TRPV3, TRPV4, TRPV5, and TRPV6—all of which are widely expressed in the mammalian central and peripheral nervous systems [58].

TRPV1 is usually considered to be involved in the perception of inflammatory and thermal pain, especially pain from heat above 43°C [4, 9]. TRPV1 is highly expressed in dorsal root ganglion (DRG) neurons, especially in C-fiber neurons, and activation of TRPV1 leads to sodium and calcium influx, causing cell depolarization [10, 11]. Depletion of TRPV1 results in decreased sensitivity to noxious heat and delays radial heat and hot-plate tests [12]. Luo et al. showed the change of the TRPV1 expression after CFA-induced inflammatory pain. TRPV1 protein was increased from day 1 to day 21 and reduced at day 28. Subcutaneous or intrathecal injection of TRPV1 antagonist capsazepine (CPZ) could reliably reduce CFA-induced thermal hyperalgesia [13, 14].

TRPV4 is highly associated with osmotic pressure and mechanical sensitivity and has been expressed in heterologous systems [15, 16]. Mice lacking TRPV4 have diminished regulation of serum osmolarity and are less sensitive to noxious stimuli [17, 18]. TRPV4 also participates in many different types of pain mediation, such as pain resulting from mechanical hyperalgesia and complications of vincristine chemotherapy, diabetes, alcoholism, and acquired immune deficiency syndrome therapy [19, 20]. Moreover, TRPV4 mutant mice showed normal behavior on thermal test after CFA injection and also participated in carrageenan- and inflammation-mediators-induced thermal and mechanical hyperalgesia [2123].

Acupuncture is an ancient Chinese method for curing pain for more than 3000 years. However, the detailed mechanism of acupuncture effects remains an important unresolved issue [24]. Several studies have shown that injection with the local anesthetic procaine inhibits the analgesic effect of acupuncture [2529].

Recently, several studies revealed that TPRV1 and TRPV4 are both involved in mechanical and thermal hyperalgesia [13, 14, 2123], but few reports showed the relationship between acupuncture with TRPV1 and TRPV4. We have investigated whether TRPV1 and TRPV4 are key mediators for the effects of acupuncture therapy on inflammatory pain, as indicated by our previous research [30]. Our results demonstrate that electroacupuncture (EA) is effective in inducing analgesia in inflammation-induced hyperalgesia by downregulating TRPV1 and TRPV4 expression.

2. Methods and Materials

2.1. Animals and EA Pretreatment

Adult ICR (BioLASCO Taiwan Co., Ltd.) female mice aged 8 to 12 weeks were used in the experiment. The usage of these animals was approved by the Institute of Animal Care and Use Committee of China Medical University, Taiwan, following the Guide for the Use of Laboratory Animals (National Academy Press). EA pretreatment was applied by stainless steel acupuncture needles (1.5′′ inch, 30 G, Yu-kuang, Taiwan) that were inserted into the muscle layer at a depth of 2-3 mm at the ST36 acupoint. EA was performed after the injection of carrageenan or CFA and performed every day at the same time (12:00–14:00) for totally four days. Electrical square pulses were delivered for 15 min with duration of 1 ms and 2 Hz in frequency generated from the stimulator. The stimulation amplitude was 2 mA. The same treatment was given to nonacupoint (the gluteal muscle) to set as the sham control group [30].

2.2. Inflammatory Pain Models

Mice were anesthetized with 1-2% isoflurane and administered a single injection of 20 μL saline (pH 7.4, buffered with 20 mM HEPES), 3% carrageenan (lambda carrageenan, type IV; Sigma), or CFA (complete Freund’s adjuvant; 0.5 mg/mL heat-killed M. tuberculosis Sigma, St. Louis, MO) in the plantar surface of the hind paw to induce intraplantar inflammation [1, 31]. Behavior tests were conducted at day 4 after induction of inflammation, and DRGs were harvested on day 4 [30].

2.3. Animal Behavior of Mechanical, Thermal Hyperalgesia, and Hot/Cold Plate

Mechanical sensitivities were tested at 4 days after intraplantar injections. All experiments were performed at room temperature (approximately 25°C) and the stimuli were applied only when the animals were calm but not sleeping or grooming. Mechanical sensitivity was measured by testing the force of responses to stimulation with six applications of electronic von Frey filaments (North Coast Medical, Gilroy, CA, USA). Thermal pain was measured with six applications using Hargreaves’ test IITC analgesiometer (IITC Life Sciences, SERIES8, Model 390G) [32]. Both hot/cold-induced pains were measured using a hot/cold plate (Panlab, Harvarf Apparatus). Five minutes of animal behavior were recorded using a digital camera and were analyzed offline using a personal computer [32, 33].

2.4. Immunohistochemistry and Image Analysis

Animals were anesthetized with an overdose of choral hydrate and intracardially perfused with saline followed by 4% paraformaldehyde. L3-L5 DRG neurons were immediately dissected and postfixed with 4% paraformaldehyde. Postfixed tissues were then placed in 30% sucrose overnight for cryoprotection. The DRGs were then embedded in OCT and rapidly frozen at −20°C. Frozen sections were cut in a 15 μm thick on a cryostat. Samples were next incubated with blocking solution containing 3% BSA, 0.1% Triton X-100, and 0.02% sodium azide in PBS for 120 min at room temperature. After blocking, DRGs were incubated with primary antibodies prepared in blocking solution at 4°C overnight against TRPV1 (1 : 1000, Alomone) and TRPV4 (1 : 1000, Alomone). The secondary antibodies were goat anti-rabbit (Molecular Probes, Carlsbad, CA, USA). Slides were visualized by the use of fluorescence-conjugated secondary antibodies and mounted on cover slips. The images of TRPV1- and TRPV4-positive neurons were calculated to differentiate cell size using NIH ImageJ software (Bethesda, MD, USA) and showed the ratio of TRPV1- and TRPV4-positive staining in a different size.

2.5. Western Blot Analysis

L3-L5 DRG neurons were immediately excised to extract proteins. Total proteins were prepared by homogenized DRG in lysis buffer containing 50 mM Tris-HCl pH 7.4, 250 mM NaCl, 1% NP-40, 5 mM EDTA, 50 mM NaF, 1 mM Na3VO4, 0.02% NaN3, and 1× protease inhibitor cocktail (AMRESCO). The extracted proteins (30 μg per sample assessed by a BCA protein assay) were subjected to 8% SDS-Tris glycine gel electrophoresis and transferred to a PVDF membrane. The membrane was blocked with 5% nonfat milk in TBS-T buffer (10 mM Tris pH 7.5, 100 mM NaCl, 0.1% Tween 20), incubated with anti-TRPV1 and TRPV4 antibody (1 : 1000, Alomone) in TBS-T with 1% bovine serum albumin, and incubated for 1 hour at room temperature. Peroxidase-conjugated anti-rabbit antibody (1 : 5000) was used as a secondary antibody. The bands were visualized by an enhanced chemiluminescent substrate kit (PIERCE) with LAS-3000 Fujifilm (Fuji Photo Film Co., Ltd.). Where applicable, the image intensities of specific bands were quantified with NIH ImageJ software (Bethesda, MD, USA).

2.6. DRG Primary Cultures and Whole-Cell Patch-Clamp Recording

CD1 mice aged 8–12 weeks were killed by use of CO2 to minimize their suffering. Lumbar (L3–L5) DRG neurons were dissected from ipsilateral site and placed in a tube containing DMEM and then transferred to DMEM with type I collagenase (0.125%, 120 min) for digestion at incubator at 37°C. Neurons were then plated on poly-L-lysine-coated cover slides. All recordings were completed within 24 hours after plating. Glass pipettes (Warner Products 64–0792) were prepared (2–5 MΩ) with the use of a vertical puller (NARISHIGE PC-10). Whole-cell recordings involved the use of an Axopatch MultiClamp 700B (Axon Instruments). Stimuli were controlled and digital records captured with the use of Signal 3.0 software and a CED1401 converter (Cambridge Electronic Design). Cells with a membrane potential more positive than −40 mV were not accepted. The bridge was balanced in current clamping recording and series resistance was compensated 70% in voltage-clamping recording with Axopatch 700B compensation circuitry. Recording cells were superfused in artificial cerebrospinal fluid (ACSF) containing (in mM) 130 NaCl, 5 KCl, 1 MgCl2, 2 CaCl2, 10 glucose, and 20 HEPES, adjusted to pH 7.4 with NaOH. ACSF solutions were applied by the use of gravity. The recording electrodes were filled with (in mM) 100 KCl, 2 Na2-ATP, 0.3 Na3-GTP, 10 EGTA, 5 MgCl2, and 40 HEPES, adjusted to pH 7.4 with KOH. Osmolarity was approximately 300–310 mOsm. Capsaicin was prepared from a 100-μM stock solution (in 100% ethanol) to a final concentration of 1 μM in ACSF. 4α-phorbol 12, 13-didecanoate (4αPDD) was prepared from a 300-μM stock solution (in 100% ethanol) to a final concentration of 3 μM in ACSF. All drugs were purchased from Sigma Chemical (St. Louis, MO, USA).

2.7. Statistical Analysis

All statistic data are presented as the mean ± standard error. Statistical significance between control, inflammation, and EA group was tested using the ANOVA test, followed by a post hoc Tukey’s test ( was considered statistically significant).

3. Results

3.1. Low-Frequency EA at the ST36 Acupoint Decreased Carrageenan—and CFA-Induced Inflammatory Pain by the von Frey Filament and Hargreaves’ Tests

Intraplantar injection of normal saline did not initiate mechanical hyperalgesia (Figure 1(a), black circles: baseline,  g; day 4,  g; ; ). Intraplantar injection of carrageenan successfully evoked inflammation-mediated mechanical hyperalgesia (Figure 1(a), red circles: baseline,  g; day 4,  g; ; ). Low-frequency (2 Hz) EA at the ST36 acupoint reliably decreased carrageenan-induced inflammatory pain (Figure 1(a), blue circles: baseline,  g; day 4,  g; ; ). This decrease was not observed in the sham-EA group (Figure 1(a), green circles: baseline,  g; day 4,  g; ; ). These results suggested that EA at the ST36 acupoint had the potential to ameliorate inflammatory pain with acupoint specificity. We also examined CFA-induced inflammatory pain. The injection of CFA, but not normal saline, also induced mechanical hyperalgesia (Figure 1(b): control, black circles, ; CFA, red circles, ; for each group). EA at the ST36 acupoint decreased CFA-mediated inflammatory pain, but sham EA did not (Figure 1(b): EA, blue circles, ; sham, green circles, ; for each group). Thermal hyperalgesia was induced in carrageenan-injected mice but not in control mice (Figure 1(c): carrageenan,  s; control,  s; for each group; ). The carrageenan-induced thermal hyperalgesia could be attenuated by EA at the ST36 acupoint but not by sham EA (Figure 1(c): EA, blue circles,  s; sham, green circles,  s; for each group; ). Similar results were obtained with the CFA-induced thermal hyperalgesia (Figure 1(d)).

3.2. EA Attenuated Carrageenan-Elicited Inflammatory Pain by the Hot/Cold-Plate Pain Test

Intraplantar pretreatment with carrageenan significantly ( ) induced thermal hyperalgesia according to the licking latency parameter with a hot plate at 50°C at day 4 after injection (Figure 2(a): control, black,  s; carrageenan, red,  s; for each group; ). As shown in Figure 2(a), 2 Hz EA eliminated the effect of pain induced by carrageenan (blue,  s), but sham EA did not (green,  s; for each group; ). Furthermore, injection of carrageenan decreased the jumping latency induced with the hot plate at 50°C from  s to  s (Figure 2(b): black and red, respectively; for each group; ). The jumping latency was attenuated by 2 Hz EA but not by sham EA (Figure 2(b): blue and green,  s and  s, respectively; for each group; ), suggesting acupoint specificity. Next to verify the effect of carrageenan and EA on thermal hyperalgesia with a cold plate at 4°C, we analyzed rearing and licking numbers in the four groups. We consistently found that intraplantar injection of carrageenan significantly increased the rearing number from to (Figure 2(c): black and red, respectively; per group; ). Interestingly, 2 Hz EA also had a potential effect on cold hyperalgesia induced by carrageenan injection compared with sham EA-treated mice (Figure 2(c): EA, blue, ; sham, green, ; per group; ). Injection of carrageenan dramatically increased the licking number from to , suggesting thermal hyperalgesia with assessment with the cold plate at 4°C (Figure 2(d): black and red, respectively; per group; ). EA cured the carrageenan-induced hyperalgesia estimated with the cold plate, but sham EA did not (Figure 2(d): blue and green, and , resp.; per group; ).

3.3. EA Attenuated CFA-Elicited Inflammatory Pain by the Hot/Cold-Plate Pain Test

Intraplantar injection of CFA consistently induced thermal hyperalgesia according to the licking latency parameter (Figure 3(a): control, black,  s; CFA, red,  s; per group; ). EA at the ST36 acupoint decreased this hyperalgesia, but sham EA did not (Figure 3(b): EA, blue,  s; sham EA, green,  s; per group; ). CFA injection decreased the jumping latency with the hot plate at 50°C from  s to  s (Figure 3(b): control, black; CFA, red; per group; ). The jumping latency was increased by EA stimulation but not by sham EA (Figure 3(b): EA, blue,  s; sham EA, green,  s; per group; ). We also characterized the cold-mediated hyperalgesia in each group. CFA injection increased the rearing number from to (Figure 3(c): black and red, respectively; for each group; ). EA decreased rearing induced by CFA injection, but sham EA did not (Figure 3(c): EA, blue, ; sham, green, ; per group; ). CFA injection increased the licking number from to with the cold-plate assessment (Figure 3(d): black and red, respectively; ; ). EA could reverse the CFA-induced hyperalgesia evaluated with the cold plate, but sham EA did not (Figure 3(d): EA, blue, ; sham EA, green, ; per group; ).

3.4. EA at the ST36 Acupoint Altered Electrophysiological Properties in Inflamed DRG Neurons

We examined the membrane properties of acutely isolated DRG neurons through whole-cell patch clamp recordings. Compared with the control group, DRG neuronal excitability was increased in mice 4 days after CFA-induced inflammation. The resting membrane potential and capacitance were similar among the control, CFA-induced, and EA-treated groups, indicating similar properties of the neurons. The AP threshold and rheobase were decreased in the CFA-inflamed group, indicating increased excitability, and these were attenuated in the EA group (Figure 4(a)). In addition, both the AP rise and fall times were significantly shorter for neurons in the inflammation group compared with those in the control group, and this result was reversed in the EA-treated group (Figure 4(b)). Moreover, no significant differences were found among the three groups in AP amplitude and after hyperpolarization (AHP) duration. To investigate the electrophysiological properties of TRPV1 and TPRV4, we injected TRPV1 or TPRV4 specific agonist capsaicin or 4αPDD to primary cultured DRG neurons to induce inward current. Notably, the percentage of TRPV1-positive neurons and the amplitude of TRPV1-induced inward current induced by the TRPV1 agonist capsaicin were potentiated by CFA-elicited inflammation and further ameliorated by EA treatment (Figure 4(c)). Similar results were also observed in TRPV4 agonist 4αPDD induced neurons. The statistically analyzed data are presented in Table 1.

Con ( )CFA ( )EA ( )

Resting membrane potential (mV)−46.70 ± 1.72−44.60 ± 1.42−42.04 ± 2.41
Capacitance (pF)35.39 ± 1.8337.29 ± 1.8437.93 ± 4.29
AP threshold (mV)−19.93 ± 1.35−25.04 ± 2.58**−17.66 ± 2.86#
AP rheobase (pA)483.03 ± 41.80401.83 ± 22.92*600.10 ± 58.79##
AP amplitude (mV)78.35 ± 2.2873.82 ± 3.3174.79 ± 4.74
AP rise time (ms)2.30 ± 0.112.07 ± 0.02*2.49 ± 0.14##
AP fall time (ms)6.36 ± 0.373.96 ± 0.39**8.41 ± 2.28#
AHP (ms)71.69 ± 8.2460.22 ± 9.4377.14 ± 10.14
TRPV1 amplitude (pA)90.79 ± 12.99189.53 ± 39.38*67.74 ± 11.53#
TRPV4 amplitude (pA)99.35 ± 14.54374.24 ± 108.59*129.48 ± 24.93#

* P < 0.05 compared with the control group; **P < 0.01 compared with the control group; #P < 0.05 between the inflammation and EA groups; ##P < 0.01 between the inflammation and EA groups. Con: control; CFA: complete Freund’s adjuvant; EA: electroacupuncture; AP: action potential; AHP: afterhyperpolarization.
3.5. TRPV1 and TRPV4 Expression in DRG Neurons from Carrageenan-Induced Hyperalgesia Was Decreased by EA

To correlate the development of inflammatory pain and the curative effects of EA with changes in TRPV1 and TRPV4 in DRG neurons, we first used immunohistochemistry to verify TRPV1 and TRPV4 expression. The expression of TRPV1 was observed in DRG neurons (Figure 5(a)). Following intraplantar injection of carrageenan, the TRPV1 staining intensity significantly increased in DRG neurons (Figure 5(b)). This increased expression of TRPV1 reverted to that of the normal control group with 2 Hz EA (Figure 5(c)). TRPV4 was also present in DRG neurons (Figure 5(d)) and its expression increased after carrageenan injection (Figure 5(e)). The overexpression of TRPV4 was attenuated by EA stimulation (Figure 5(f)).

3.6. EA Abated the CFA-Mediated Inflammatory Pain Response by Altering TRPV1 and TRPV4 Levels

We next determined the alterations in TRPV1 and TRPV4 levels in CFA-elicited inflammatory hyperalgesia. TRPV1 levels were normal in DRG neurons (Figure 6(a)) and increased following CFA injection (Figure 6(b)). This phenomenon was reversed by 2-Hz EA stimulation at the ST36 acupoint (Figure 6(c)). TRPV4 also was observed in DRG neurons (Figure 6(d)). TRPV4 levels increased following CFA injection (Figure 6(e)) and were dramatically attenuated by 2-Hz EA stimulation (Figure 6(f)). Cell area versus frequency histograms (Figure 7) showed that TRPV1 proteins were mainly presented in small neurons (cell area < 800 μm2). At day 4 after carrageenan injection, the TRPV1-reactive neurons were increased within small-medium (800–1200 μm2) neurons compared with control group ( ). The potentiation of TRPV1 protein level was attenuated with EA stimulation. The similar results were obtained in a CFA-treated group. The TRPV4-positive neurons were mainly expressed in medium to large neurons and the ratio of all the population did not alter with both carrageenan and CFA-induced inflammatory pain models. However, our Western blot found TRPV4 was increased with both carrageenan and CFA-elicited inflammatory pain models; we suggested that TRPV4 was increased in all types of DRGs.

3.7. EA at ST36 Ameliorated Overexpression of TRPV1 and TRPV4 in DRG Neurons by Western Blotting

We used Western blotting to further analyze the levels of TRPV1 and TRPV4 proteins in DRG neurons. TRPV1 protein was expressed normally in the control group. After carrageenan-induced hyperalgesia, TRPV1 protein expression was greatly increased (Figure 8(a), % compared with control group; , ). This increase was effectively downregulated by 2 Hz EA stimulation at the ST36 acupoint (Figure 8(a), % compared with carrageenan group, ; ). TRPV4 protein was also overexpressed after carrageenan injection (Figure 8(c), % compared with control group, ; ) and attenuated by 2 Hz EA stimulation at the ST36 acupoint (Figure 8(c), % compared with carrageenan group, ; ). Similar phenomena were observed with CFA-induced inflammation (Figures 8(b) and 8(d)). These results demonstrated that 2 Hz EA at the ST36 acupoint could successfully reverse inflammation-induced TRPV1 and TRPV4 overexpression in both the carrageenan- and CFA-induced models.

4. Discussion

EA at ST36 can effectively decrease inflammation-induced pain, but the detailed mechanism remains unknown [34, 35]. Both TRPV1 and TRPV4 are highly correlated with mechanical and thermal pain. We hypothesized that EA at ST36 could attenuate inflammation-induced pain through the mediation of TRPV1 and TRPV4 channels.

TRPV1 and TRPV4 are both cation channels that are activated at temperatures over 43°C or 25°C, and both are essential for thermal and mechanical hyperalgesia [22, 36]. Both are highly expressed in DRG neurons after inflammation induction that results in thermal and mechanical hyperalgesia [22, 36]. Many reports have found that TRPV1 and TRPV4 antisense oligonucleotides or antagonists can effectively ameliorate thermal and mechanical hyperalgesia. Moreover, depletion of TRPV1 or TPRV4 in mice results in higher withdrawal latencies in the von Frey’s or Hargraves’ tests. These data indicate that both TRPV1 and TRPV4 are essential for mediating thermal and mechanical sensations [22, 23, 36]. Our results show that thermal and mechanical sensitivities, as measured by hot-plate-induced licking and jumping latency, are altered following inflammatory pain and that these phenomena are attenuated by 2 Hz EA stimulation. We suggest that these behavioral changes are mediated through TRPV1 and TRPV4 downregulation by a 2 Hz EA. Our data also show that a cold plate at 4°C increases rearing and licking numbers in mice and that this result is abated by 2 Hz EA. These results suggest that EA may also regulate different channels such as TRPA1 or TRPM8 [23].

It has long been recognized that TRPV1 is involved in pain sensations and can increase synaptic transmission in the hippocampus, hypothalamus, and spinal cord with increased miniature excitatory postsynaptic current (mEPSC) frequency after capsaicin application [37, 38]. Activation of TRPV1 induces long-term depression in the nucleus accumbens and hippocampal dentate gyrus [37, 38]. TRPV1 is suggested to mediate both thermal and mechanical hyperalgesia in inflammatory hyperalgesia. Deletion of TRPV1 is crucial for decreasing CFA-elicited mechanical and thermal hyperalgesia in knee joint and muscle inflammation models. TRPV1 antagonists or antisense oligonucleotides have similar effects in decreasing inflammatory pain symptoms [10, 36]. TRPV1 is reported to be activated by mediators and secondary messengers in inflammatory conditions and with tissue injury and ischemia. Under these conditions, peripheral acidosis with low pH is also thought to activate TRPV1 and contribute to pain sensation [23]. Our results suggest that both carrageenan and CFA injection can enhance TRPV1 protein levels in peripheral DRGs. Furthermore, EA manipulation can reliably ameliorate this inflammation-induced upregulation of TRPV1. This phenomenon has also been observed in a tumor pain model, and the powerful therapeutic effect of TRPV1 blockage is being explored [34].

Peripheral synaptic transmission from DRG neurons to the spinal cord dorsal horn (SCDH) is crucial for pain signaling [3]. At these synapses, glutamate is released from presynaptic nerve terminals by several types of stimuli and binds to postsynaptic receptors. These signals are further transferred into electrical signals to the brain for pain sensation and pain responses [39]. In the inflammatory pain process, the probability of augmented glutamate release leads to central nervous system sensitization. Our results show that carrageenan- and CFA-induced inflammatory pain reliably induces mechanical and thermal pain accompanied by TRPV4 increase, as shown by immunostaining and Western blotting. This phenomenon can be reversed through low-frequency (2-Hz) EA stimulation. This is a novel mechanism underlying acupuncture therapy. Recently, activation of TRPV4 by application of its agonist, 4αPDD, was shown to significantly potentiate the frequency of mEPSCs, implying that presynaptic transmission is responsible for TRPV4 action [38]. Cao and colleagues have demonstrated that TRPV4-elicted membrane currents and synaptic transmission occur primarily through protein kinase C activation [38]. Accordingly, increased TRPV4 may result in enhanced excitability of pain signaling and further induce central sensitization. Mechanical hyperalgesia is decreased in animals by intrathecal administration of TRPV4 antisense oligonucleotides or TRPV4 gene depletion [19, 40]. Ding et al. also have reported that TRPV4 is crucial for the thermal pain process induced by chronic compression of DRG neurons in rats through mechanisms that activate TRPV4-NO-cGMP-PKG pathways [41].

Recent studies have shown that ATP is released at ST36 after acupuncture, and ATP is metabolized to adenosine by specific enzymes [42]. Activation of the A1R by adenosine decreases TPRV1 activation by depleting PIP2 (phosphatidylinositol 4, 5-bisphosphate), because PIP2 is important for TRPV1 channel activation [43]. Our results show that TRPV1 expression and physiological function are affected by acupuncture, and we suggest that this phenomenon is influenced by A1R activation. Chen et al. have also reported that it activates PAR2 (protease-activated receptor 2), which then activates PKA (protein kinase A) and PKC (protein kinase C), causing mechanical and thermal (both heat and cold) hypersensitivity. Furthermore, this hypersensitivity is effectively inhibited by TRPV1 and TRPV4 antagonists [44]. A1R is a GPCR (G-protein-coupled receptor), and activation of A1R decreases adenylyl cyclase activity through activation of pertussis toxin-sensitive Gi proteins that then inhibit PKA activity [4547]. We suggest that the mechanism underlying acupuncture-mediated analgesia may be A1R activation, which then inhibits PKA activation resulting in downregulation of TRPV1 and TRPV4.

Studies of the mechanism of pain signaling may lead to the development of additional drugs and therapies. Hurt and colleagues have reported that PAP (prostatic acid phosphatase) is an ectonucleotidase that can hydrolyze extracellular AMP to adenosine in the nociceptive system. Injection of PAP to the Weizhong acupoint has antinociceptive effects in mouse inflammatory pain models [48]. Therese and colleagues have found that TRPV1 is more highly expressed at the BL40 acupoint skin than in the nonacupoint control skin and that TRPV1 expression can be influenced by EA stimulation [49]. This indicates that TRPV1 is associated with the BL40 acupoint. Our data show that acupuncture can mediate TPRV1 and TRPV4 expression in DRG neurons. Furthermore, we may be able to develop more effective therapies by combining a TPRV1 antagonist or agonist with acupoints to prolong the effects of acupuncture therapy.

5. Conclusion

This current study suggests that TRPV1 and TRPV4 were augmented in mice DRG neurons in both the carrageenan and CFA-induced inflammatory pain models. Accordingly, this is the first paper regarding the functional role of acupuncture in pain signaling and its novel findings regarding TRPV1 and TRPV4 channel downregulation. The phenomenon can be further attenuated by EA at the ST36 acupoint, rather than sham group. These results indicate highly valuable data from investigating acupuncture-mediated analgesia mechanisms and can be further applied to clinical medicine.

Conflict of Interests

The authors declare that they have no conflict of interests.


This work was supported by NSC 101-2320-B-039-014-MY3 and CMU99-N2-07 and in part by the Taiwan Department of Health Clinical Trial and Research Center of Excellence (DOH101-TD-B-111-004). The authors contributed equally to the paper and are considered as the corresponding authors.


  1. R. Y. Walder, L. A. Rasmussen, J. D. Rainier, A. R. Light, J. A. Wemmie, and K. A. Sluka, “ASIC1 and ASIC3 play different roles in the development of hyperalgesia after inflammatory muscle injury,” Journal of Pain, vol. 11, no. 3, pp. 210–218, 2010. View at: Publisher Site | Google Scholar
  2. K. H. Steen, A. E. Steen, H. W. Kreysel, and P. W. Reeh, “Inflammatory mediators potentiate pain induced by experimental tissue acidosis,” Pain, vol. 66, no. 2-3, pp. 163–170, 1996. View at: Publisher Site | Google Scholar
  3. D. Julius and A. I. Basbaum, “Molecular mechanisms of nociception,” Nature, vol. 413, no. 6852, pp. 203–210, 2001. View at: Publisher Site | Google Scholar
  4. M. J. Caterina, M. A. Schumacher, M. Tominaga, T. A. Rosen, J. D. Levine, and D. Julius, “The capsaicin receptor: a heat-activated ion channel in the pain pathway,” Nature, vol. 389, no. 6653, pp. 816–824, 1997. View at: Publisher Site | Google Scholar
  5. A. Akbar, Y. Yiangou, P. Facer, J. R. F. Walters, P. Anand, and S. Ghosh, “Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain,” Gut, vol. 57, no. 7, pp. 923–929, 2008. View at: Publisher Site | Google Scholar
  6. P. Facer, M. A. Casula, G. D. Smith et al., “Differential expression of the capsaicin receptor TRPV1 and related novel receptors TRPV3, TRPV4 and TRPM8 in normal human tissues and changes in traumatic and diabetic neuropathy,” BMC Neurology, vol. 7, article 11, 2007. View at: Publisher Site | Google Scholar
  7. H. E. Gibson, J. G. Edwards, R. S. Page, M. J. Van Hook, and J. A. Kauer, “TRPV1 channels mediate long-term depression atsynapses on hippocampal interneurons,” Neuron, vol. 57, no. 5, pp. 746–759, 2008. View at: Publisher Site | Google Scholar
  8. E. Mezey, Z. E. Tóth, D. N. Cortright et al., “Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 7, pp. 3655–3660, 2000. View at: Google Scholar
  9. M. J. Caterina, T. A. Rosen, M. Tominaga, A. J. Brake, and D. Julius, “A capsaicin-receptor homologue with a high threshold for noxious heat,” Nature, vol. 398, no. 6726, pp. 436–441, 1999. View at: Publisher Site | Google Scholar
  10. J. B. Davis, J. Gray, M. J. Gunthorpe et al., “Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia,” Nature, vol. 405, no. 6783, pp. 183–187, 2000. View at: Publisher Site | Google Scholar
  11. M. J. Gunthorpe, C. D. Benham, A. Randall, and J. B. Davis, “The diversity in the vanilloid (TRPV) receptor family of ion channels,” Trends in Pharmacological Sciences, vol. 23, no. 4, pp. 183–191, 2002. View at: Publisher Site | Google Scholar
  12. T. Christoph, G. Bahrenberg, J. De Vry et al., “Investigation of TRPV1 loss-of-function phenotypes in transgenic shRNA expressing and knockout mice,” Molecular and Cellular Neuroscience, vol. 37, no. 3, pp. 579–589, 2008. View at: Publisher Site | Google Scholar
  13. H. Luo, J. Cheng, J. S. Han, and Y. Wan, “Change of vanilloid receptor 1 expression in dorsal root ganglion and spinal dorsal horn during inflammatory nociception induced by complete Freund's adjuvant in rats,” NeuroReport, vol. 15, no. 4, pp. 655–658, 2004. View at: Publisher Site | Google Scholar
  14. H. Luo, I. S. Xu, Y. Chen et al., “Behavioral and electrophysiological evidence for the differential functions of TRPV1 at early and late stages of chronic inflammatory nociception in rats,” Neurochemical Research, vol. 33, no. 10, pp. 2151–2158, 2008. View at: Publisher Site | Google Scholar
  15. S. M. Brierley, A. J. Page, P. A. Hughes et al., “Selective role for TRPV4 ion channels in visceral sensory pathways,” Gastroenterology, vol. 134, no. 7, pp. 2059–2069, 2008. View at: Publisher Site | Google Scholar
  16. R. Strotmann, C. Harteneck, K. Nunnenmacher, G. Schultz, and T. D. Plant, “OTRPC4, a nonselective cation channel that confers sensivity to extracellular osmolarity,” Nature Cell Biology, vol. 2, no. 10, pp. 695–702, 2000. View at: Publisher Site | Google Scholar
  17. A. Mizuno, N. Matsumoto, M. Imai, and M. Suzuki, “Impaired osmotic sensation in mice lacking TRPV4,” American Journal of Physiology, vol. 285, no. 1, pp. C96–C101, 2003. View at: Google Scholar
  18. M. Suzuki, A. Mizuno, K. Kodaira, and M. Imai, “Impaired pressure sensation in mice lacking TRPV4,” Journal of Biological Chemistry, vol. 278, no. 25, pp. 22664–22668, 2003. View at: Publisher Site | Google Scholar
  19. N. Alessandri-Haber, O. A. Dina, E. K. Joseph, D. B. Reichling, and J. D. Levine, “Interaction of transient receptor potential vanilloid 4, integrin, and Src tyrosine kinase in mechanical hyperalgesia,” Journal of Neuroscience, vol. 28, no. 5, pp. 1046–1057, 2008. View at: Publisher Site | Google Scholar
  20. N. Alessandri-Haber, E. Joseph, O. A. Dina, W. Liedtke, and J. D. Levine, “TRPV4 mediates pain-related behavior induced by mild hypertonic stimuli in the presence of inflammatory mediator,” Pain, vol. 118, no. 1-2, pp. 70–79, 2005. View at: Publisher Site | Google Scholar
  21. N. Alessandri-Haber, O. A. Dina, E. K. Joseph, D. Reichling, and J. D. Levine, “A transient receptor potential vanilloid 4-dependent mechanism of hyperalgesia is engaged by concerted action of inflammatory mediators,” Journal of Neuroscience, vol. 26, no. 14, pp. 3864–3874, 2006. View at: Publisher Site | Google Scholar
  22. H. Todaka, J. Taniguchi, J. I. Satoh, A. Mizuno, and M. Suzuki, “Warm temperature-sensitive transient receptor potential vanilloid 4 (TRPV4) plays an essential role in thermal hyperalgesia,” Journal of Biological Chemistry, vol. 279, no. 34, pp. 35133–35138, 2004. View at: Publisher Site | Google Scholar
  23. S. R. Eid and D. N. Cortright, “Transient receptor potential channels on sensory nerves,” Handbook of Experimental Pharmacology, vol. 194, pp. 261–281, 2009. View at: Publisher Site | Google Scholar
  24. Z. Q. Zhao, “Neural mechanism underlying acupuncture analgesia,” Progress in Neurobiology, vol. 85, no. 4, pp. 355–375, 2008. View at: Publisher Site | Google Scholar
  25. “Effect of needling positions in acupuncture on pain threshold of human skin,” Zhonghua Yi Xue Za Zhi, vol. 3, pp. 151–157, 1973. View at: Google Scholar
  26. C. H. Tung, “Integrative action of thalamus in the process of acupuncture for analgesia,” The American Journal of Chinese Medicine, vol. 2, no. 1, pp. 1–39, 1974. View at: Google Scholar
  27. D. J. Mayer, D. D. Price, and A. Rafii, “Antagonism of acupuncture analgesia in man by the narcotic antagonist naloxone,” Brain Research, vol. 121, no. 2, pp. 368–372, 1977. View at: Publisher Site | Google Scholar
  28. C. P. Carlsson, “Acupuncture therapy today. Background, clinical use, mechanisms,” Lakartidningen, vol. 98, no. 46, pp. 5178–5186, 2001. View at: Google Scholar
  29. X. Cao, “Scientific bases of acupuncture analgesia,” Acupuncture & Electro-Therapeutics Research, vol. 27, no. 1, pp. 1–14, 2002. View at: Google Scholar
  30. W. H. Chen, C. L. Hsieh, C. P. Huang et al., “Acid-sensing ion channel 3 mediates peripheral anti-hyperalgesia effects of acupuncture in mice inflammatory pain,” Journal of Biomedical Science, vol. 18, p. 82, 2011. View at: Google Scholar
  31. S. T. Meller, C. P. Cummings, R. J. Traub, and G. F. Gebhart, “The role of nitric oxide in the development and maintenance of the hyperalgesia produced by intraplantar injection of carrageenan in the rat,” Neuroscience, vol. 60, no. 2, pp. 367–374, 1994. View at: Publisher Site | Google Scholar
  32. M. J. Zylka, N. A. Sowa, B. Taylor-Blake et al., “Prostatic acid phosphatase is an ectonucleotidase and suppresses pain by generating adenosine,” Neuron, vol. 60, no. 1, pp. 111–122, 2008. View at: Publisher Site | Google Scholar
  33. L. E. Ta, P. A. Low, and A. J. Windebank, “Mice with cisplatin and oxaliplatin-induced painful neuropathy develop distinct early responses to thermal stimuli,” Molecular Pain, vol. 5, article 9, 2009. View at: Publisher Site | Google Scholar
  34. Z. Zhang, C. Wang, G. Gu et al., “The effects of electroacupuncture at the ST36 (Zusanli) acupoint on cancer pain and transient receptor potential vanilloid subfamily 1 expression in Walker 256 tumor-bearing rats,” Anesthesia & Analgesia, vol. 114, no. 4, pp. 879–885, 2012. View at: Google Scholar
  35. H. W. Kim, D. K. Uh, S. Y. Yoon et al., “Low-frequency electroacupuncture suppresses carrageenan-induced paw inflammation in mice via sympathetic post-ganglionic neurons, while high-frequency EA suppression is mediated by the sympathoadrenal medullary axis,” Brain Research Bulletin, vol. 75, no. 5, pp. 698–705, 2008. View at: Publisher Site | Google Scholar
  36. L. Yu, F. Yang, H. Luo et al., “The role of TRPV1 in different subtypes of dorsal root ganglion neurons in rat chronic inflammatory nociception induced by complete Freund's adjuvant,” Molecular Pain, vol. 4, article 61, 2008. View at: Publisher Site | Google Scholar
  37. D. Bennion, T. Jensen, C. Walther et al., “Transient receptor potential vanilloid 1 agonists modulate hippocampal CA1 LTP via the GABAergic system,” Neuropharmacology, vol. 61, no. 4, pp. 730–738, 2011. View at: Publisher Site | Google Scholar
  38. D. S. Cao, S. Q. Yu, and L. S. Premkumar, “Modulation of transient receptor potential vanilloid 4-mediated membrane currents and synaptic transmission by protein kinase C,” Molecular Pain, vol. 5, article 5, 2009. View at: Publisher Site | Google Scholar
  39. R. Cregg, A. Momin, F. Rugiero, J. N. Wood, and J. Zhao, “Pain channelopathies,” Journal of Physiology, vol. 588, no. 11, pp. 1897–1904, 2010. View at: Publisher Site | Google Scholar
  40. N. Alessandri-Haber, O. A. Dina, X. Chen, and J. D. Levine, “TRPC1 and TRPC6 channels cooperate with TRPV4 to mediate mechanical hyperalgesia and nociceptor sensitization,” Journal of Neuroscience, vol. 29, no. 19, pp. 6217–6228, 2009. View at: Publisher Site | Google Scholar
  41. X. L. Ding, Y. H. Wang, L. P. Ning et al., “Involvement of TRPV4-NO-cGMP-PKG pathways in the development of thermal hyperalgesia following chronic compression of the dorsal root ganglion in rats,” Behavioural Brain Research, vol. 208, no. 1, pp. 194–201, 2010. View at: Google Scholar
  42. N. Goldman, M. Chen, T. Fujita et al., “Adenosine A1 receptors mediate local anti-nociceptive effects of acupuncture,” Nature Neuroscience, vol. 13, no. 7, pp. 883–888, 2010. View at: Publisher Site | Google Scholar
  43. N. A. Sowa, S. E. Street, P. Vihko, and M. J. Zylka, “Prostatic acid phosphatase reduces thermal sensitivity and chronic pain sensitization by depleting phosphatidylinositol 4,5-bisphosphate,” Journal of Neuroscience, vol. 30, no. 31, pp. 10282–10293, 2010. View at: Publisher Site | Google Scholar
  44. Y. Chen, C. Yang, and Z. J. Wang, “Proteinase-activated receptor 2 sensitizes transient receptor potential vanilloid 1, transient receptor potential vanilloid 4, and transient receptor potential ankyrin 1 in paclitaxel-induced neuropathic pain,” Neuroscience, vol. 193, pp. 440–451, 2011. View at: Publisher Site | Google Scholar
  45. S. McGaraughty, M. Cowart, M. F. Jarvis, and R. F. Berman, “Anticonvulsant and antinociceptive actions of novel adenosine kinase inhibitors,” Current Topics in Medicinal Chemistry, vol. 5, no. 1, pp. 43–58, 2005. View at: Publisher Site | Google Scholar
  46. A. Rogel, Y. Bromberg, O. Sperling, and E. Zoref-Shani, “Phospholipase C is involved in the adenosine-activated signal transduction pathway conferring protection against iodoacetic acid-induced injury in primary rat neuronal cultures,” Neuroscience Letters, vol. 373, no. 3, pp. 218–221, 2005. View at: Publisher Site | Google Scholar
  47. H. E. Tawfik, J. Schnermann, P. J. Oldenburg, and S. J. Mustafa, “Role of A1 adenosine receptors in regulation of vascular tone,” American Journal of Physiology, vol. 288, no. 3, pp. H1411–H1416, 2005. View at: Publisher Site | Google Scholar
  48. J. K. Hurt and M. J. Zylka, “PAPupuncture has localized and long-lasting antinociceptive effects in mouse models of acute and chronic pain,” Molecular Pain, vol. 8, no. 1, p. 28, 2012. View at: Google Scholar
  49. T. S. Abraham, M. L. Chen, and S. X. Ma, “TRPV1 expression in acupuncture points: response to electroacupuncture stimulation,” Journal of Chemical Neuroanatomy, vol. 41, no. 3, pp. 129–136, 2011. View at: Publisher Site | Google Scholar

Copyright © 2012 Wei-Hsin Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.